Literature DB >> 16466318

Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors.

Steven C Schachter1.   

Abstract

Antiepileptic drugs remain the cornerstone of epilepsy treatment for minimizing, if not eliminating, seizures. However, many factors other than the degree of seizure control influence the quality of life for patients with epilepsy. This review focuses on psychosocial factors that have been associated with quality of life in this population, especially mood disorders, stigma seizure worry, self-esteem and self-mastery. Irrespective of their level of seizure control from antiepileptic drugs, patients may also benefit from targeted psychosocial interventions that reduce the negative impact of these factors on their quality of life.

Entities:  

Mesh:

Year:  2006        PMID: 16466318     DOI: 10.1586/14737175.6.1.111

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  13 in total

1.  Sleep-dependent memory consolidation in the epilepsy monitoring unit: A pilot study.

Authors:  Rani A Sarkis; Javad Alam; Milena K Pavlova; Barbara A Dworetzky; Page B Pennell; Robert Stickgold; Ellen J Bubrick
Journal:  Clin Neurophysiol       Date:  2016-05-31       Impact factor: 3.708

Review 2.  Currently available antiepileptic drugs.

Authors:  Steven C Schachter
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Validity and Reliability of the Quality of Life in Epilepsy Inventory (QOLIE-10) For Turkey.

Authors:  Mukadder Mollaoğlu; Muratcan Mollaoğlu; Zehra Durna
Journal:  Noro Psikiyatr Ars       Date:  2017-01-12       Impact factor: 1.339

4.  'Whom will I give him to? The difficulty is mine' : Psychosocial difficulties experienced by care givers of patients with epilepsy in Cape Town, South Africa.

Authors:  Mpoe Johannah Keikelame; Leslie Swartz
Journal:  J Health Psychol       Date:  2016-07-10

5.  Psychiatric comorbidity in patients with epilepsy: a population-based study.

Authors:  Mohamad Karouni; Subaneesan Arulthas; Pål G Larsson; Elisif Rytter; Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Eur J Clin Pharmacol       Date:  2010-07-29       Impact factor: 2.953

6.  The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Authors:  Anthony Marson; Girvan Burnside; Richard Appleton; Dave Smith; John Paul Leach; Graeme Sills; Catrin Tudur-Smith; Catrin Plumpton; Dyfrig A Hughes; Paula Williamson; Gus A Baker; Silviya Balabanova; Claire Taylor; Richard Brown; Dan Hindley; Stephen Howell; Melissa Maguire; Rajiv Mohanraj; Philip E Smith
Journal:  Lancet       Date:  2021-04-10       Impact factor: 79.321

7.  Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.

Authors:  Georg Anton Giæver Beiske; Trygve Holmøy; Antonie Giæver Beiske; Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Mult Scler Int       Date:  2015-06-29

Review 8.  Devices for Self-Monitoring Sedentary Time or Physical Activity: A Scoping Review.

Authors:  James P Sanders; Adam Loveday; Natalie Pearson; Charlotte Edwardson; Thomas Yates; Stuart J H Biddle; Dale W Esliger
Journal:  J Med Internet Res       Date:  2016-05-04       Impact factor: 5.428

9.  Psychiatric Comorbidities and Outcomes in Epilepsy Patients: An Insight from a Nationwide Inpatient Analysis in the United States.

Authors:  Rikinkumar S Patel; Ahmed Elmaadawi; Zeeshan Mansuri; Mandeep Kaur; Kaushal Shah; Suhayl Nasr
Journal:  Cureus       Date:  2017-09-14

10.  Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).

Authors:  Silviya Balabanova; Claire Taylor; Graeme Sills; Girvan Burnside; Catrin Plumpton; Phil E M Smith; Richard Appleton; John Paul Leach; Michael Johnson; Gus Baker; Munir Pirmohamed; Dyfrig A Hughes; Paula R Williamson; Catrin Tudur-Smith; Anthony Guy Marson
Journal:  BMJ Open       Date:  2020-08-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.